期刊文献+

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells 被引量:4

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
暂未订购
导出
摘要 Imatinib,a breakpoint cluster region(BCR)-Abelson murine leukemia(ABL) tyrosine kinase inhibitor(TKI),has revolutionized the treatment of chronic myelogenous leukemia(CML).However,development of multidrug resistance(MDR) limits the use of imatinib.In the present study,we aimed to investigate the mechanisms of cellular resistance to imatinib in CML.Therefore,we established an imatinib-resistant human CML cell line(K562-imatinib) through a stepwise selection process.While characterizing the phenotype of these cells,we found that K562-imatinib cells were 124.6-fold more resistant to imatinib than parental K562 cells.In addition,these cells were cross-resistant to second-and third-generation BCR-ABL TKIs.Western blot analysis and reverse transcription-polymerase chain reaction(RT-PCR) demonstrated that P-glycoprotein(P-gp) and MDR1 mRNA levels were increased in K562-imatinib cells.In addition,accumulation of [14C]6-mercaptopurine(6-MP) was decreased,whereas the ATP-dependent efflux of [14C]6-MP and [3H]methotrexate transport were increased in K562-imatinib cells.These data suggest that the overexpression of P-gp may play a crucial role in acquired resistance to imatinib in CML K562-imatinib cells. Imatinib, a breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myelogenous leukemia (CML). However, development of multidrug resistance(MDR) limits the use of imatinib. In the present study, we aimed to investigate the mechanisms of cellular resistance to imatinib in CML. Therefore, we established an imatinib-resistant human CML cell line (K562-imatinib) through a stepwise selection process. While characterizing the phenotype of these cells, we found that K562-imatinib cells were 124.6-fold more resistant to imatinib than parental K562 cells. In addition, these cells were cross-resistant to second- and third-generation BCR-ABL TKIs. Western blot analysis and reverse transcription-polymerase chain reaction(RT-PCR) demonstrated that P-glycoprotein (P-gp) and MDR1 mRNA levels were increased in K562-imatinib cells. In addition, accumulation of [14C]6-mercaptopurine (6-MP) was decreased, whereas the ATP-dependent efflux of [14C] 6-MP and [3H]methotrexate transport were increased in K562-imatinib cells. These data suggest that the overexpression of P-gp may play a crucial role in acquired resistance to imatinib in CML K562-imatinib cells.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 2012年第2期110-118,共9页
基金 supported by start-up funding from St.John's University(Z.S.Chen)
关键词 慢性粒细胞白血病 白血病细胞 P-糖蛋白 多药耐药 过度表达 K562细胞 酪氨酸激酶抑制剂 诱导 Human chronic myelogenous leukemia, multidrug resistance, imatinib, P-glycoprotein, drug transporters
  • 相关文献

参考文献47

  • 1Rowley JD.A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.Nature,1973,243:290-293.
  • 2Goldman JM,Melo JV.Chronic myeloid leukemia-advances in biology and new approaches to treatment.N Engl J Med,2003,349:1451-1464.
  • 3Hehlmann R,Hochhus A,Baccarani M.Chronic myeloid leukemia.Lancet,2007,370:342-350.
  • 4Roskoski R Jr.STI-571:an anticancer protein-tyrosine kinase inhibitor.Biochem Biophys Res Commun,2003,309:709-717.
  • 5Walz C,Sattler M.Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia(CML).Crit Rev Oncol Hematol,2006,57:145-164.
  • 6Sawyers CL.Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.Cancer Cell,2002,1:13-15.
  • 7Shah NP,Sawyers CL.Mechanisms of resistance to STI571in Philadelphia chromosome-associated leukemias.Oncogene,2003,22:7389-7395.
  • 8Druker BJ,Tamura S,Buchdunger E,et al.Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med,1996,2:561-566.
  • 9Deininger MW,Goldman JM,Lydon N,et al.The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.Blood,1997,90:3691-3698.
  • 10Gambacorti-Passerini C,le Coutre P,Mologni L,et al.Inhibition of the ABL kinase activity blocks the proliferation of Bcr/Abl+leukemic cells and induces apoptosis.Blood Cells Mol Dis,1997,23:380-394.

同被引文献11

引证文献4

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部